Objective To observe the influence on patient’s response to antiviral therapy and quality of life using combined treatment of Kangshi Kangxian Formula

pegylated interferon-alpha-2a（ PEG-IFNα-2a） and ribavirin for chronic hepatitis C（ CHC）. Methods Totally 64 selected CHC patients were randomly divided into treatment group with 33 cases and control group with 31 cases. Control group was given PEG-IFNα-2a subcutaneous injection180 μg each time

once per week and ribavirin orally 0. 3 g each time

3 times per day. Treatment group had Kangshi Kangxian Formula orally

1 dose per day

with the basic treatment same as control group. Treatment lasted for 24 weeks. The changes of liver tissue biopsy

hepatic fibrosis instantaneous elastic（ Fibro Scan） value

serum alanine aminotransferase（ ALT）

quantitative of hepatitis C virus（ HCV RNA） and chronic liver disease questionnaire（ CLDQ） scores were recorded after treatments of both groups. Results Two groups’ responses of virology and biochemistry showed no statistical significance（ P > 0. 05）. Inflammation and fibrosis of the liver were significantly improved after treatment（ P < 0. 05） compared within each group before. Improvement of liver fibrosis in treatment group is greater than control group（ P < 0. 05）. On the improvement of Fibro Scan value

treatment group was obviously better than control group（ P < 0. 05）. Every aspect of CLDQ scores of treatment group had different levels of increases（ P < 0. 01）

while control group only had some increases on systemic symptom

activity ability and emotion scores（ P < 0. 05）. After treatment

treatment group’ s CLDQ scores on abdomenal pain

sleepinese

emotion and anxiety were notedly better than contreol group（ P < 0. 01）. Conclusion Using Kangshi Kangxian Formula combined with PEG-IFNα-2a and ribavirin to treat CHC not only increased patient’s response to antiviral therapy

but also improve the condition of liver fibrosis and patient’s quality of life.